Mazdutide vs reta — does the Chinese trial data hold up?

Mazdutide is a GLP-1/glucagon dual agonist (no GIP). The Phase 3 GLORY-1 data from China showed pretty impressive weight reductions but the trial methodology and the population are different from Western GLP-1 trials.

Anyone in the lit looking at whether the Chinese metabolic disease trial standards produce comparable effect estimates? Or are we just going to wait for Western Phase 3?